Mode of administration of dulaglutide: implications for treatment adherence

References

• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet20063681696170517098089
   PubMed Web of Science ®Google Scholar
• KaragiannisTLiakosABekiariEEfficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsDiabetes Obes Metab201517111065107426395850
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20153814014925538310
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAACE comprehensive diabetes management algorithm 2013Endocr Pract20131932733623598536
   PubMed Web of Science ®Google Scholar
• AlbertNMImproving medication adherence in chronic cardiovascular diseaseCrit Care Nurse2008285546418827087
   PubMed Web of Science ®Google Scholar
• SokolMCMcGuiganKAVerbruggeRREpsteinRSImpact of medication adherence on hospitalization risk and health care costMed Care200543652153015908846
   PubMed Web of Science ®Google Scholar
• AscheCLaFleurJConnerCA review of diabetes treatment adherence and the association with clinical and economic outcomesClin Ther20113317410921397776
   PubMed Web of Science ®Google Scholar
• PichaKMCunninghamMRDruckerDJProtein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasisDiabetes20085771926193418426860
   PubMed Web of Science ®Google Scholar
• GlaesnerWVickAMMillicanREngineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion proteinDiabetes Metab Res Rev201026428729620503261
   PubMed Web of Science ®Google Scholar
• BarringtonPChienJYTibaldiFShowalterHDSchneckKEllisBLY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjectsDiabetes Obes Metab20111343443821251179
   PubMed Web of Science ®Google Scholar
• ChienJYCuiSChaudharyALoghinCLY2189265, a long-acting glucagon-like peptide-1 analog does not affect gastric emptying of acetaminophen after multiple dosing in healthy subjectsDiabetes201059Suppl 1 Abs 600-P
   Google Scholar
• BarringtonPChienJYShowalterHDA 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetesDiabetes Obes Metab201113542643321251178
   PubMed Web of Science ®Google Scholar
• GrunbergerGChangAGarcia SoriaGBotrosFTBsharatRMilicevicZMonotherapy with the once-weekly GLP-1 analogue dula for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled studyDiabet Med201229101260126722804250
   PubMed Web of Science ®Google Scholar
• UmpierrezGEBlevinsTRosenstockJEGO Study GroupThe effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO studyDiabetes Obes Metab201113541842521251180
   PubMed Web of Science ®Google Scholar
• SkrivanekZGaydosBLChienJYDose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)Diabetes Obes Metab201416874875624762094
   PubMed Web of Science ®Google Scholar
• GeiserJSHeathmanMACuiXClinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: Analyses of data from clinical trialsClin Pharmacokinet201655562563426507721
   PubMed Web of Science ®Google Scholar
• Trulicity (dulaglutide) product information Available from: http://uspl.lilly.com/trulicity/trulicity.html#piAccessed December 10, 2015
   Google Scholar
• Trulicity (dulaglutide) instructions for use Available from: http://uspl.lilly.com/trulicity/trulicity.html#ugAccessed December 10, 2015
   Google Scholar
• DunganKMPovedanoSTForstTOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialLancet201438499511349135725018121
   PubMed Web of Science ®Google Scholar
• WeinstockRSGuerciBUmpierrezGNauckMASkrivanekZMilicevicZSafety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III studyDiabetes Obes Metab201517984985825912221
   PubMed Web of Science ®Google Scholar
• GiorginoFBenroubiMSunJHZimmermannAGPechtnerVEfficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)Diabetes Care201538122241224926089386
   PubMed Web of Science ®Google Scholar
• BlondeLJendleJGrossJOnce-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority studyLancet20153852057206626009229
   PubMed Web of Science ®Google Scholar
• WyshamCBlevinsTArakakiREfficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)Diabetes Care20143782159216724879836
   PubMed Web of Science ®Google Scholar
• UmpierrezGTofé PovedanoSPérez ManghiFShurzinskeLPechtnerVEfficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)Diabetes Care20143782168217624842985
   PubMed Web of Science ®Google Scholar
• EmotoMTerauchiYOzekiAOuraTTakeuchiMImaokaTA 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trialEndocr J201562121101111426477324
   PubMed Web of Science ®Google Scholar
• DunganKMRazISkrivanekZSeallsWFahrbachJLAchieving the composite endpoint of HbA1c <7.0%, no weight gain, and no hypoglycaemia in the once weekly dulaglutide AWARD programDiabetes Obes Metab2016181495526362460
   PubMed Web of Science ®Google Scholar
• GrunbergerGForstTFernández LandóLEarly fasting glucose measurements can predict later glycemic response to once weekly dulaglutideDiabet Med201633339139426179454
   PubMed Web of Science ®Google Scholar
• GurungTShyangdanDSO’HareJPWaughNA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideDiabetes Metab Syndr Obes2015836338626316788
   PubMed Web of Science ®Google Scholar
• FerdinandKCWhiteWBCalhounDAEffects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitusHypertension201464473173724980665
   PubMed Web of Science ®Google Scholar
• FerdinandKCBotrosFTAtissoCMSagerPTCardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular eventsCardiovasc Diabetol2016153826912057
   PubMed Web of Science ®Google Scholar
• RaibouaaABorgekeHAlexiouDLowinJNorrbackaKCost-effectiveness of dulaglutide 1.5 mg once weekly for the treatment of patients with type two diabetes mellitus in SwedenValue Health2015187A60726533410
   PubMed Web of Science ®Google Scholar
• IngersollKSCohenJThe impact of medication regimen factors on adherence to chronic treatment: a review of literatureJ Behav Med20083121322418202907
   PubMed Web of Science ®Google Scholar
• DaviesMSpeightJPatient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitusDiabetes Obes Metab20121488289222420869
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRKrugerDFTravisLBCorrelates of insulin injection omissionDiabetes Care20103324024520103556
   PubMed Web of Science ®Google Scholar
• ReaneyMYuMLakshmananMPechtnerVvan BruntKTreatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trialsDiabetes Obes Metab201517989690326095190
   PubMed Web of Science ®Google Scholar
• Van BruntKReaneyMYuMLakshmananMCurtisBMitchellBPatient-reported outcomes with dula, exenatide, or placebo (AWARD-1)Proceedings of the 49th European Association for the Study of Diabetes (EASD) Annual Meeting2013Barcelona, Spain Abstract 985
   Google Scholar
• A Randomized, open-label, parallel-arm, noninferiority comparison of the effects of two doses of LY2189265 and insulin glargine on glycemic control in patients with type 2 diabetes on stable doses of metformin and glimepiride (AWARD-2) Available from: ClinicalTrails.gov. Clinical-Trials.gov Identifier: NCT01075282Accessed November 20, 2015
   Google Scholar
• The impact of LY2189265 versus insulin glargine in combination with insulin lispro for the treatment to target of type 2 diabetes mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes-4) Available from: ClinicalTrails.gov. ClinicalTrials.gov Identifier: NCT01191268Accessed November 20, 2015
   Google Scholar
• MatfinGVan BruntKZimmermannAGThrelkeldRIgnautDASafe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetesJ Diabetes Sci Technol2015951071107925901022
   PubMedGoogle Scholar